Regulatory MSD secures EC clearance for Keytruda combination therapy for ovarian cancer Pharmaceutical TechnologyMSD has received the EC approval for Keytruda along with paclitaxel, with or without bevacizumab, as a treatment for PD-L1-positive ovarian cancer.RegulatoryOncologyRead full story pharminent April 6, 2026 (Last updated: April 6, 2026) Pharmaceutical Technology MSD has received the EC approval for Keytruda along with paclitaxel, with or without bevacizumab, as a treatment for PD-L1-positive ovarian cancer. RegulatoryOncologyRead full story Post navigation Previous: Trump revives pharma tariffs with 100% charges, but leaves loopholesNext: Aspect Biosystems receives funding for cellular medicine project Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026